Selected Publications

Gurevitz C, Bhatt DL, Giugliano RP, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Lira Pineda A, Doyle RT Jr, Giugliano G, Mason RP, Tardif JC, Martens FMAC, Ballantyne CM, Budoff MJ, Gibson CM: Benefit of Icosapent Ethyl Across Types and Sizes of Myocardial Infarction in REDUCE-IT. Eur J Prev Cardiol 2026.

Miller M, Aggarwal M, Allen K, Bhattacharya R, Dastmalchi LN, Kris-Etherton PM, Klodas E, Mazaffarian D, Ostfeld RJ, Petersen KS, Reddy KR, Ros E, Vinaithirthan V, Freeman AM: A Clinician’s Guide for Trending Cardiovascular Nutritional Controversies in 2026. Journal of the American College of Cardiology Advances 2026.

Burrowes SAB, Zisman E, Fantry LE, Bui Q, Wu A, Sorkin J, Miller M, Bagchi S.: Changes in Atherosclerotic Cardiovascular Disease Risk Scores in a Predominantly Black Cohort with HIV and Associated Comorbidities: A Preliminary Study. Cardiology 150: 194-202, 2025.

Miller M, Bhatt DL, Brinton EA, Jacobson TA, Steg PG, Ketchum S, Pineda AL, Tardif J-C, Ballantyne CM on Behalf of the Reduce-IT Investigators: Icosapent Ethyl Reduces CVD Risk in Cardiovascular-Kidney-Metabolic Syndrome: REDUCE-IT CKM. American Journal of Preventive Cardiology 2025.

Hegele RA, Ahmad Z, Ashraf A, Baldassarra A, Brown AS, Chait A, Freedman SD, Kohn B, Miller M, Patni N, Soffer DE, Wamng J, Broder MS, Chang E, Uermilov I, Campos C, Gibbs SN.: Development and Validation of Clinical Criteria to Identify Familial Chylomicronemia Syndrome (FCS) in North America. Journal of Clinical lipidology 2025.

Aggarwal R, Bhatt DL, Steg PG, Miller M, Brinton E, Dunbar R, Ketchum S, Tardif J-C, Martens F, Ballantyne CM, Szarek M, Mason RP.: Cardiovascular Outcomes with Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial. JAHA: Journal of the American Heart Association. 2025.

Zisman E, Hossain M, Funderburg NT, Christenson R, Jeudy J, Burrowes S, Hays AG, George N, Freeman ML, Rebuck H, Mitchell SE, Miller M, Bagchi S.: Association of Lipoprotein (a) with peri-coronary inflammation in persons with and without HIV infection. J Clin Lipidol 2024.

Sayah N, Bhatt DL, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Jiao L, Pineda AL, Doyle RT Jr, Tardif JC, Ballantyne CM, Steg PG.: Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial. Eur Heart J. 2024.

Weintraub WS, Bhatt DL, Zhang Z, Dolman S, Boden WE, Bress AP, Bellows BK, Derington CG, Philip S, Steg G, Miller M, Brinton EA, Jacobson TA, Tardif JC, Ballantyne CM, Kolm P: Cost-Effectiveness of Icosapent Ethyl in REDUCE-IT USA: Results From Patients Randomized in the United States. J Am Heart Assoc 13, 2024.

Miller M: Pemafibrate and other triglyceride-lowering therapies to reduce risk of cardiovascular and metabolic disease. Curr Opin Cardiol 2024.